Legend Biotech Corporation (LEGN) Stock

About Legend Biotech Corporation

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.

Legend Biotech Corporation is headquartered in US.

Legend Biotech Corporation (LEGN) stock trades at $23.58 with a market capitalization of $4.36B. The stock is valued at a negative price-to-earnings (P/E) ratio of -17.34, reflecting a net loss over the last twelve months, price-to-book of 4.50, price-to-sales of 3.83. Over the past 52 weeks the stock has ranged between $16.24 and $45.30, and currently trades 47.9% below its 52-week high.

On profitability, Legend Biotech Corporation generates a return on equity (ROE) of -24.91% (negative, reflecting a net loss), return on capital employed of -12.48%, an operating margin of -11.92%, a net profit margin of -21.97%.

Official website: www.legendbiotech.com

Legend Biotech Corporation by the numbers, 2017–2025

Between 2017 and 2025 Legend Biotech Corporation reported revenue of $24.0M rising to $1.0B, a change of +4187.5% across 9 years. Compounded, revenue has grown 68.8% a year over five years, 106.4% over three, 64.1% over the last twelve months. Net profit fell to $-297.0M.

Operating margin went from 58.4% in 2017 to -13.3% in 2025, a fall of 71.7 percentage points. The most recent net margin is -21.97%. On a trailing twelve-month basis to Mar '26, revenue is $1.1B and net profit $-250.0M.

Borrowings stand at $414.0M, cash on hand is $834.6M, cash from operations was $-100.0M in the latest year, positive in 1 of the last 9.

Return on equity has averaged -40.1% over five years, and was -29.6% in the most recent year.

The share price itself has compounded at -13.2% a year over five years, -31.9% over three, -46.4% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Legend Biotech Corporation (LEGN) — frequently asked questions